Laurus Labs has informed that it has signed an agreement with MPP (Medicine Patient Pool) for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir. In this regard, the company has attached on January 21,2022.
The above information is a part of company’s filings submitted to BSE.